NCT06766864

A Study of Subcutaneous DR-01 in Healthy Volunteers

A Randomized, Double-blind, Placebo-controlled, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Subcutaneous Administration of Single Ascending Doses of DR-01 in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Dren Bio · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a randomized, double-blind, placebo-controlled, Phase 1 study to evaluate the safety, tolerability, PK, immunogenicity, and PD of SC administration of single ascending doses of DR-01 in healthy volunteers.

Conditions

• Healthy Volunteer

Interventions

Type	Name	Description
DRUG	DR-01	DR-01 is a monoclonal antibody
OTHER	Placebo	Placebo

Timeline

• Start date: 2025-03-03
• Primary completion: 2025-08-27
• Completion: 2025-08-27
• First posted: 2025-01-09
• Last updated: 2025-09-29

Locations

1 site across 1 country: New Zealand